Oxford Immunotec Global PLC (OXFD) Lowered to “Sell” at Zacks Investment Research

Oxford Immunotec Global PLC (NASDAQ:OXFD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “

OXFD has been the subject of a number of other research reports. Cowen and Company restated a “buy” rating and issued a $19.00 price objective on shares of Oxford Immunotec Global PLC in a research report on Thursday, September 28th. BTIG Research set a $21.00 price objective on shares of Oxford Immunotec Global PLC and gave the company a “buy” rating in a research report on Tuesday. ValuEngine downgraded shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research report on Tuesday. Robert W. Baird reiterated a “buy” rating and set a $20.00 price target on shares of Oxford Immunotec Global PLC in a research report on Wednesday. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $26.00 price target on shares of Oxford Immunotec Global PLC in a research report on Thursday, August 3rd. Three investment analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. Oxford Immunotec Global PLC currently has an average rating of “Hold” and an average price target of $19.75.

Oxford Immunotec Global PLC (NASDAQ OXFD) opened at $13.25 on Friday. The company has a quick ratio of 2.51, a current ratio of 4.72 and a debt-to-equity ratio of 0.38.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last announced its quarterly earnings data on Tuesday, August 1st. The company reported ($0.32) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.32). The firm had revenue of $26.10 million during the quarter, compared to the consensus estimate of $25.05 million. Oxford Immunotec Global PLC had a negative net margin of 45.74% and a negative return on equity of 38.42%. The firm’s revenue was up 35.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.29) earnings per share. equities analysts predict that Oxford Immunotec Global PLC will post -2.11 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Oxford Immunotec Global PLC (OXFD) Lowered to “Sell” at Zacks Investment Research” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2017/11/04/oxford-immunotec-global-plc-oxfd-lowered-to-sell-at-zacks-investment-research.html.

In other news, CEO Peter Wrighton-Smith sold 55,000 shares of Oxford Immunotec Global PLC stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $16.78, for a total transaction of $922,900.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global PLC stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $15.82, for a total transaction of $47,460.00. Following the sale, the director now owns 18,000 shares of the company’s stock, valued at $284,760. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 93,110 shares of company stock valued at $1,563,564. Insiders own 8.11% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Essex Investment Management Co. LLC lifted its position in shares of Oxford Immunotec Global PLC by 27.7% during the 2nd quarter. Essex Investment Management Co. LLC now owns 141,197 shares of the company’s stock valued at $2,375,000 after acquiring an additional 30,637 shares during the period. Redmile Group LLC increased its stake in shares of Oxford Immunotec Global PLC by 7.5% during the 2nd quarter. Redmile Group LLC now owns 2,155,949 shares of the company’s stock worth $36,263,000 after purchasing an additional 151,100 shares in the last quarter. Wasatch Advisors Inc. increased its stake in shares of Oxford Immunotec Global PLC by 34.3% during the 2nd quarter. Wasatch Advisors Inc. now owns 423,831 shares of the company’s stock worth $7,129,000 after purchasing an additional 108,154 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Oxford Immunotec Global PLC by 97.8% during the 1st quarter. Renaissance Technologies LLC now owns 363,300 shares of the company’s stock worth $5,628,000 after purchasing an additional 179,600 shares in the last quarter. Finally, American International Group Inc. increased its stake in shares of Oxford Immunotec Global PLC by 7.1% during the 1st quarter. American International Group Inc. now owns 13,668 shares of the company’s stock worth $212,000 after purchasing an additional 904 shares in the last quarter. Institutional investors own 79.21% of the company’s stock.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

What are top analysts saying about Oxford Immunotec Global PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Oxford Immunotec Global PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit